Form 4: ALX Oncology SVP Sells Shares for Tax Obligations

ALX Oncology Holdings Inc.'s SVP of Finance and CAO, Shelly Pinto, sold 903 shares of common stock to cover tax obligations related to vested restricted stock units.

Summary

• Shelly Pinto, SVP, Finance and CAO of ALX Oncology Holdings Inc., reported a sale of common stock.
• The transaction involved the disposition of 903 shares of ALXO common stock.
• The shares were sold at a price of $2.17 per share.
• The sale was conducted on March 19, 2026.
• Following this transaction, Pinto beneficially owns 86,805 shares of ALXO common stock.
• The purpose of the sale was to satisfy tax obligations associated with the vesting of performance-based restricted stock units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as the sale is a routine 'sell-to-cover' for tax obligations following the vesting of performance-based restricted stock units, indicating successful achievement of performance metrics.

Positives

• The sale was for tax obligations related to vested performance-based restricted stock units, indicating the vesting of equity compensation.

Negatives

• An insider sold shares, which could be perceived negatively by some investors, although the reason is specified as tax-related.

Future Outlook

No specific future outlook or guidance is provided in this insider transaction report.

Industry Context

StockSavvy.ai notes that insider sales for tax purposes are a common occurrence when restricted stock units or options vest, and typically do not signal a change in management's long-term outlook on the company, unlike discretionary sales.

Comparison to Industry Standards

• This type of transaction, a 'sell-to-cover' for tax obligations upon equity vesting, is a standard practice across publicly traded companies, including peers in the biotechnology and oncology sectors.
• It is not indicative of a lack of confidence in the company's future performance, unlike large, discretionary open-market sales by executives which might raise concerns.

Stakeholder Impact

• Shareholders: Minor impact, as it's a routine tax-related sale, not a discretionary one, and typically does not signal a change in company fundamentals.
• Employees: No direct impact on the broader employee base from this specific transaction.

Key Dates

Recommendation

The reported transaction is a routine 'sell-to-cover' by an executive to satisfy tax obligations upon the vesting of performance-based restricted stock units. This type of insider sale is generally not indicative of a change in the company's fundamentals or management's confidence, and therefore does not warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

ALX Oncology Holdings Inc., ALXO, Shelly Pinto, Form 4, Insider Trading, Stock Sale, Tax Obligations, Restricted Stock Units, Equity Compensation